2025
Reducing alcohol-associated liver disease burden in the general population
Asrani S, Mellinger J, Sterling S, Lucey M, Bradley K, Bhala N, Bray J, Chen P, DiMartini A, Fernandez A, Ghadiali M, Haque L, Khalili M, Lee B, Lin L, Pillai A, Satre D, Sengupta S, Serper M, Simonetto D, Thiele M, Welsh J, Wu T, Zsohar J, Shah V. Reducing alcohol-associated liver disease burden in the general population. The Lancet Gastroenterology & Hepatology 2025 PMID: 40976252, DOI: 10.1016/s2468-1253(25)00193-1.Peer-Reviewed Original ResearchAlcohol use disorderCare modelAlcohol-associated liver diseaseElevated AUDIT-C scoreEmergency care modelAlcohol Use Disorders Identification TestAlcohol useIntegrated care modelPrevalence of alcohol use disordersAUDIT-C scoresUnhealthy alcohol usePer capita alcohol consumptionReferral to treatmentGeneral medical settingsMental health treatmentPopulation-based screeningBlood-based testDisorders Identification TestHealth-care costsPatient engagementReferral pathwaysBrief interventionAUDIT-CLiver disease burdenHealth treatmentSynergistic toxicity in alcohol-associated liver disease and PFAS exposure
Stem A, Tieghi R, Chatzi V, Kleinstreuer N, Valvi D, Thompson D, Vasiliou V. Synergistic toxicity in alcohol-associated liver disease and PFAS exposure. Toxicological Sciences 2025, kfaf110. PMID: 40737496, DOI: 10.1093/toxsci/kfaf110.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseLiver diseaseChronic ethanol intakeCentral mechanismsHepatotoxic effectsPolyfluoroalkyl substancesHigh-risk populationOxidative stressDysregulated lipid metabolismEthanol intakeLiver functionLiver injuryAcetaldehyde-induced cytotoxicityHepatic functionHepatocellular damageOxidative stress inductionLiver pathologyGlobal morbidityPathogenic pathwaysPolyfluoroalkyl substances exposuresExposure to polyfluoroalkyl substancesFatty acid oxidationHealthcare accessEffects of polyfluoroalkyl substancesMultiple mechanismsConcomitant treatment of alcohol associated liver disease and alcohol use disorder in the nontransplant setting: A scoping review
Fathma S, McKee S, Grimshaw A, Boateng S, Fiellin D, Haque L, Mehal W, Banini B. Concomitant treatment of alcohol associated liver disease and alcohol use disorder in the nontransplant setting: A scoping review. Alcohol Clinical And Experimental Research 2025, 49: 1631-1639. PMID: 40650432, DOI: 10.1111/acer.70112.Peer-Reviewed Original ResearchConceptsTreatment of alcohol-associated liver diseaseAlcohol-associated liver diseaseAlcohol use disorderTreatment of alcohol use disordersConcomitant treatmentLiver transplant evaluationLiver diseaseNontransplant settingLiver transplantationProgression of alcohol-associated liver diseaseTransplant evaluationEffective treatmentUse disorderLiver-related deathComprehensive searchAssociated liver diseaseComprehensive search of electronic databasesFrequency of hospitalizationCare modelSearch of electronic databasesDisease courseEmergency department visitsCochrane LibraryAddiction medicineMultidisciplinary care teamAn AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease
Ilagan-Ying Y. An AUDacious Proposal: How to Improve Gastroenterology Fellow Training for Alcohol Use Disorder and Alcohol-Associated Liver Disease. Digestive Diseases And Sciences 2025, 70: 2940-2943. PMID: 40512451, DOI: 10.1007/s10620-025-09144-2.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderGastroenterology fellowsOne-hour educational interventionHealth professional traineesMultidisciplinary care modelAttitudes of providersAttitudes of cliniciansLife-saving careAddiction medicine specialistsManagement of alcohol use disorderALD-related mortalityUse disorderAlcohol use disorder pharmacotherapiesTertiary academic care centerVulnerable patient populationPrimary careCare modelHealth professionalsEducational interventionMedicine providersAddiction providersProfessional traineesLiver diseaseTreatment gapTargeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease
Yang Y, Duan Y, Lang S, Fondevila M, Schöler D, Harberts A, Cabré N, Chen S, Shao Y, Vervier K, Miyamoto Y, Zhang X, Chu H, Yang L, Tan C, Eckmann L, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Stärkel P, Lawley T, Schnabl B. Targeted inhibition of pathobiont virulence factor mitigates alcohol-associated liver disease. Cell Host & Microbe 2025, 33: 957-972.e6. PMID: 40441146, PMCID: PMC12162233, DOI: 10.1016/j.chom.2025.05.003.Peer-Reviewed Original ResearchConceptsEthanol-induced liver diseaseAlcohol-associated liver diseaseAlcohol-associated hepatitisLiver diseaseGenome of Escherichia coliE. coliMetagenomic sequencing of fecal samplesInternational cohort of patientsGenetic manipulation of bacteriaGnotobiotic mouse modelOutcomes of patientsManipulation of bacteriaCohort of patientsScavenger receptor MARCOGlobal health burdenVirulence factorsMetagenomic sequencingGut microbiotaGenetic manipulationDisease progressionMouse modelKupffer cellsKpsMBacterial spreadInternational cohortImmunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, Wang H. Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease. Cellular & Molecular Immunology 2025, 22: 1190-1204. PMID: 40399593, DOI: 10.1038/s41423-025-01291-w.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseTherapeutic targetLiver diseaseOptimal treatment strategyAnti-inflammatory therapyNon-parenchymal liver cellsExtra-hepatic organsImprove patient outcomesImmune cellsImmunological mechanismsInflammatory cellsImmunological pathwaysTreatment strategiesInflammatory mediatorsDisease onsetGlobal health challengePatient outcomesNervous systemInflammationAdipose tissueLiver cellsPrecision medicineClinical researchDiseaseHealth challengesFrom embedded interprofessional clinics to expanded alcohol-associated liver disease programs.
Winder G, Arab J, Goswami Banerjee A, Bryce K, Fipps D, Hussain F, Im G, Omary L, Patel A, Patel S, Rubman S, Serper M, Shenoy A, Suzuki J, Zimbrean P, Brown K, Abouljoud M, Mellinger J. From embedded interprofessional clinics to expanded alcohol-associated liver disease programs. Liver Transplantation 2025 PMID: 40359009, DOI: 10.1097/lvt.0000000000000638.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAUD careLong-term patient relationshipsCare delivery strategiesHazardous alcohol usePatient populationInterprofessional clinicPalliative carePrimary careCare elementsCare frameworkIll patient populationPatient relationshipHealthcare systemLiver transplantationHarm reductionDisease programsCareAlcohol useLiver diseaseEnhanced supportChronic liver diseaseEating disorder treatmentCollaborative modelDisorder treatmentLiver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder
Cote M, Cloonan D, Li S, Razak S, Singh R, Coe T, Zimbrean P, Andrews S, Ivkovic A, Bartels S, Chadha R, Bethea E, Yeh H, Lim N, Dageforde L. Liver Transplant Provider Perspectives on Posttransplant Management of Alcohol Use Disorder. Transplantation Direct 2025, 11: e1766. PMID: 40078821, PMCID: PMC11896101, DOI: 10.1097/txd.0000000000001766.Peer-Reviewed Original ResearchAUD careAlcohol use disorderAlcohol-associated liver diseasePost-LTLiver transplantationManagement of alcohol use disorderLiver diseaseTreatment of alcohol use disordersTreat alcohol use disorderUse disorderPost-LT treatmentPost-LT patientsMental health professionalsMedication-Assisted TherapyAnalysis of categorical variablesAmerican SocietyNurse coordinatorPerceived BarriersHealth professionalsProvider perspectiveChi-square testPosttransplant managementUnivariate analysis of categorical variablesVolume tertilesAlcohol abstinence
2024
US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020
Banini B, Chauhan S, Amatya A, Dashti F, Zahrawi K, Zahrawi F, Mehal W, McKee S. US mortality trends from alcohol‐associated hepatitis by sex, age, race, and ethnicity, 1999–2020. Alcohol Clinical And Experimental Research 2024, 49: 358-367. PMID: 39739407, DOI: 10.1111/acer.15515.Peer-Reviewed Original ResearchAmerican Indians/Alaska NativesMortality rate ratiosIndians/Alaska NativesCenters for Disease Control and Prevention Wide-ranging Online DataUS Centers for Disease Control and Prevention Wide-ranging ONline DataWide-ranging Online DataMortality rateUS mortality trendsAlcohol-associated hepatitisJoinpoint regression analysisYoung adultsCross-sectional studyAlcohol-associated liver diseaseYoung adult femalesHigh-risk populationOnline dataMortality trendsSteepest increaseUnited StatesYear compared to baselineCalendar trendsSociodemographic factorsRacial/ethnic groupsEpidemiological researchRate ratiosValidation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis
Mezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and Epidemiologic Definition of the Novel Steatotic Liver Disease Nomenclature in a National United States Cohort With Cirrhosis. Clinical Gastroenterology And Hepatology 2024, 23: 1588-1599.e7. PMID: 39689774, PMCID: PMC12167392, DOI: 10.1016/j.cgh.2024.10.035.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseCardiometabolic risk factorsAlcohol use disorderSteatotic liver diseaseLiver diseaseLow high-density lipoproteinChild-Turcotte-Pugh classIncidence rateIncident hepatocellular carcinomaIncreased alcohol intakeAlcohol useClinically relevant definitionAll-Cause MortalityHigher hazard of mortalityNational cohort of veteransUnited States cohortCohort of veteransAcute cardiac eventsHigh-density lipoproteinHazard of mortalityHazardous alcohol useAlcohol intakeCardiac eventsAlcohol exposureHepatocellular carcinomaAcute Kidney Injury in Patients With Cirrhosis and Chronic Kidney Disease: Results From the HRS-HARMONY Consortium
St. Hillien S, Robinson J, Ouyang T, Patidar K, Belcher J, Cullaro G, Regner K, Chung R, Ufere N, Velez J, Neyra J, Asrani S, Wadei H, Teixeira J, Saly D, Levitsky J, Orman E, Sawinski D, Dageforde L, Allegretti A, Consortium H. Acute Kidney Injury in Patients With Cirrhosis and Chronic Kidney Disease: Results From the HRS-HARMONY Consortium. Clinical Gastroenterology And Hepatology 2024, 23: 1755-1765.e4. PMID: 39675402, PMCID: PMC12163100, DOI: 10.1016/j.cgh.2024.10.023.Peer-Reviewed Original ResearchAcute kidney injuryChronic kidney diseaseLiver function parametersKidney diseaseKidney injuryAssociated with lower 90-day mortalityRates of intensive care unit admissionLiver diseaseAlcohol-associated liver diseaseIntensive care unit admissionMELD-Na scoreRenal replacement therapyShort-term outcomesFunction parametersComparison of outcomesPeak creatinineAdmission creatinineTransplant listing statusReplacement therapyUnit admissionPrimary outcomeCirrhosisMetabolic dysfunctionHospitalized patientsPatientsRacial and ethnic disparities in alcohol-associated liver disease hospitalizations in Brazil before and after the COVID-19 pandemic
Heringer D, Costa G, Weleff J, Rodrigues V, Sengupta S, Anand A. Racial and ethnic disparities in alcohol-associated liver disease hospitalizations in Brazil before and after the COVID-19 pandemic. Annals Of Hepatology 2024, 30: 101742. PMID: 39653118, DOI: 10.1016/j.aohep.2024.101742.Peer-Reviewed Original ResearchMonthly hospitalization ratesHospitalization ratesAlcohol-associated liver diseaseHealth-related inequalitiesInterrupted time series analysisIncidence of alcohol‐associated liver diseaseAge of hospitalized patientsPre-pandemic ratesEthnic groupsCOVID-19 pandemicEthnic disparitiesPublic hospitalsStatistically significant decreaseImpact of raceBlack populationHospitalLiver diseaseStudy periodCOVID-19Total populationSignificant decreaseCombined populationWhole populationConsecutive monthsPopulationFaecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis
Kreimeyer H, Gonzalez C, Fondevila M, Hsu C, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Louvet A, Lucey M, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez D, Schnabl B. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut 2024, 74: 103-115. PMID: 39033024, PMCID: PMC11631684, DOI: 10.1136/gutjnl-2024-332730.Peer-Reviewed Original ResearchAlcohol-associated hepatitisShort-term survivalMulticentre cohortSeverity of ALDAlcohol-associated liver diseaseIndependent validation cohortInduce gut dysbiosisNon-invasive markerAlcohol-use disordersNeutrophil degranulationPrediction of short-term survivalPrognostic effectHepatic neutrophilsValidation cohortBacterial translocationNeutrophil granulesMPO levelsLiver diseaseFecal biomarkersTandem mass tagPatientsGut dysbiosisLiver damageDisease severityNeutrophilsIntegrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
Haque L, Leggio L. Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder. Hepatology 2024, 80: 1408-1423. PMID: 38935926, PMCID: PMC11841743, DOI: 10.1097/hep.0000000000000996.Peer-Reviewed Original ResearchAUD careAlcohol-associated liver diseaseAlcohol use disorderCollaborative careImpact of health disparitiesAlcohol-related deathsImpact of comorbid conditionsPublic health impactUse disorderHarm reduction approachesLiver diseaseInterprofessional teamHealth disparitiesTreatment of alcohol use disordersComprehensive careProblematic alcohol useSubstance use disordersSpectrum of alcohol-associated liver diseasesTreatment gapLiver-related outcomesMinority of patientsLiver-related morbidityAlcohol use disorder treatmentCareAlcohol useDesigning clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement
Lee B, Witkiewitz K, Mellinger J, Anania F, Bataller R, Cotter T, Curtis B, Dasarathy S, DeMartini K, Diamond I, Diazgranados N, DiMartini A, Falk D, Fernandez A, German M, Kamath P, Kidwell K, Leggio L, Litten R, Louvet A, Lucey M, McCaul M, Sanyal A, Singal A, Sussman N, Terrault N, Thursz M, Verna E, Radaeva S, Nagy L, Mitchell M. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement. Nature Reviews Gastroenterology & Hepatology 2024, 21: 626-645. PMID: 38849555, PMCID: PMC11829730, DOI: 10.1038/s41575-024-00936-x.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderLiver diseaseClinical trialsRisk of decompensation of liver diseaseAlcohol useUse disorderTreatment of alcohol use disordersExpert panel consensus statementDecompensation of liver diseaseAddiction medicine specialistsProgression of liver diseaseLiver-related outcomesNational Institute of Alcohol AbuseDesigning Clinical TrialsEffects of alcohol useConsensus of expert opinionTask ForceConsensus statementMedicine specialistsAlcohol abuseHeavy drinkingDiseaseClinical trialistsPatientsManagement of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities
Sharma P, Shenoy A, Shroff H, Kwong A, Lim N, Pillai A, Devuni D, Haque L, Balliet W, Serper M. Management of alcohol-associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities. Liver Transplantation 2024, 30: 848-861. PMID: 38471008, PMCID: PMC12313025, DOI: 10.1097/lvt.0000000000000362.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseAlcohol use disorderAUD careValue-based care modelsPrevalence of alcohol use disordersPost-LTLiver transplantationManagement of alcohol-associated liver diseasePost-transplant patient survivalLiver diseaseRisk of disease recurrenceUse disorderImprove patient outcomesPost-LT relapseCare modelSystemic barriersTherapy accessDigital healthUnmet needsLiver transplant candidatesAlcohol consumptionCenters of excellenceGlobal health burdenAddiction specialistsCareTreatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action
Haque L, Zuluaga P, Muga R, Fuster D. Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action. Addiction Science & Clinical Practice 2024, 19: 19. PMID: 38504384, PMCID: PMC10949674, DOI: 10.1186/s13722-024-00448-8.Peer-Reviewed Original ResearchConceptsAlcohol-associated liver diseaseAlcohol use disorderLiver diseasePresence of liver cirrhosisTreatment of alcohol use disordersUse disorderInnovative treatment strategiesUnhealthy alcohol usePharmacologic treatment choicesTreating unhealthy alcohol useLiver transplantationLiver cirrhosisTreatment strategiesTreatment choiceEfficacious treatmentLiver deathsPatientsAlcohol useDiseaseLiverTreatmentDisordersCirrhosisTransplantationChapter 13 Liver Sinusoidal Cells in alcohol-associated liver disease
Iwakiri Y. Chapter 13 Liver Sinusoidal Cells in alcohol-associated liver disease. 2024, 285-291. DOI: 10.1016/b978-0-323-95262-0.00013-9.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseLiver sinusoidal endothelial cellsPathogenesis of alcohol-associated liver diseaseChronic alcohol consumptionSinusoidal endothelial cellsLiver diseaseNormal function of immune cellsEndothelial cellsFunction of immune cellsSinusoidal cellsAlcohol consumptionIntrahepatic vascular toneHepatic stellate cellsEndothelial cell populationLiver sinusoidal cellsLiver cell typesImmune cellsAntigen clearanceVascular toneKupffer cells/macrophagesKupffer cellsStellate cellsCell populationsLiver homeostasisLiver
2023
Proteomic Panels for Alcohol-Associated Liver Disease: Accurate, but Different Enough From Existing Clinical Tests?
Mezzacappa C, Bhat M. Proteomic Panels for Alcohol-Associated Liver Disease: Accurate, but Different Enough From Existing Clinical Tests? Gastroenterology 2023, 165: 1576. PMID: 37683704, DOI: 10.1053/j.gastro.2023.09.002.Commentaries, Editorials and LettersInhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression
Malnassy G, Keating C, Gad S, Bridgeman B, Perera A, Hou W, Cotler S, Ding X, Choudhry M, Sun Z, Koleske A, Qiu W. Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma Expression. Cellular And Molecular Gastroenterology And Hepatology 2023, 16: 685-709. PMID: 37460041, PMCID: PMC10520367, DOI: 10.1016/j.jcmgh.2023.07.006.Peer-Reviewed Original ResearchConceptsAlcohol-fed miceLiver diseaseALD pathogenesisPPARγ expressionLiver injuryAlcohol feedingKnockout miceAlcohol-associated liver diseaseLiver tissueC57BL6/J miceAlcohol-induced accumulationAlcohol-induced steatosisOil Red O stainingWild-type miceHypoxia inducible factor 1 subunit alphaTreatment of ALDPPARγ protein expressionRed O stainingLiver-specific knockoutSubsequent lipid accumulationSubsequent RNA sequencingPotential molecular targetsAbl kinase inhibitorsQuantitative polymerase chain reactionLipid droplet formation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply